Preliminary data from retrospective analyses of tumor samples obtained from a clinical trial of the anti-PD-L1 agent durvalumab, demonstrated that PD-L1 high expression, identified by the PD-L1 (SP263) assay and scoring algorithm, was a useful predictor of treatment response [1]. Here, CD274 is linked to neoplasm.